Treatment of bone disorders with skeletal anabolic drugs
AssigneeOsteotrophin, LLC
InventorAndrew F. Stewart
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.
Claims25
-21. (canceled)
A method of increasing bone mass in a human patient in need thereof, said method comprising administering intermittently to said patient parathyroid hormone-related protein (PTHrP) at a dosage of at least 600 μg/day for a period of at least one month, wherein the bone mass density of said patient increases at a rate of at least 1% per month.
A method of treating a human patient afflicted with osteoporosis, said method comprising administering intermittently parathyroid hormone-related protein (PTHrP) to said patient at a dosage of at least about 600 μg/day for a period of about 1 to about 36 months, wherein the bone mass density of said patient increases at a rate of at least 1% per month.
A method of increasing bone mass in a human patient in need thereof, said method comprising administering intermittently to said patient parathyroid hormone-related protein (PTHrP) at a dosage of at least 600 μg/day for a period of at least one month, wherein the bone mass density of said patient increases at a rate of at least 1% per month over a period of at least three months.
A method of treating a human patient afflicted with osteoporosis, said method comprising administering intermittently parathyroid hormone-related protein (PTHrP) to said patient at a dosage of at least about 600 μg/day for a period of about 1 to about 36 months, wherein the bone mass density of said patient increases at a rate of at least 1% per month over a period of at least three months.
Dependencies are inferred from the claim text.